[go: up one dir, main page]

WO2000069454A8 - Suppression de l'igfbp-2 endogene visant a inhiber le cancer - Google Patents

Suppression de l'igfbp-2 endogene visant a inhiber le cancer

Info

Publication number
WO2000069454A8
WO2000069454A8 PCT/US2000/013574 US0013574W WO0069454A8 WO 2000069454 A8 WO2000069454 A8 WO 2000069454A8 US 0013574 W US0013574 W US 0013574W WO 0069454 A8 WO0069454 A8 WO 0069454A8
Authority
WO
WIPO (PCT)
Prior art keywords
igfbp
modulators
cancer
cancers
suppression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2000/013574
Other languages
English (en)
Other versions
WO2000069454A1 (fr
WO2000069454A9 (fr
Inventor
Shila Chakrabarty
Pomila Singh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
University of Texas at Austin
Original Assignee
University of Texas System
University of Texas at Austin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System, University of Texas at Austin filed Critical University of Texas System
Publication of WO2000069454A1 publication Critical patent/WO2000069454A1/fr
Publication of WO2000069454A8 publication Critical patent/WO2000069454A8/fr
Anticipated expiration legal-status Critical
Publication of WO2000069454A9 publication Critical patent/WO2000069454A9/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1754—Insulin-like growth factor binding proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4745—Insulin-like growth factor binding protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Plant Pathology (AREA)
  • Food Science & Technology (AREA)

Abstract

L'invention concerne le rôle de l'IGFBP-2 dans le cancer. Le traitement des cancers qui dépendent de l'IGFBP-2 bénéficieraient de thérapies ciblant l'IGFBP-2. L'invention concerne des procédés d'inhibition des cancers dépendant de l'IGFBP-2 qui reposent sur la modulation de l'activité de l'IGFBP-2. On peut obtenir la modulation en diminuant les quantités de protéine IGFBP-2 ou d'activité IGFBP-2, ainsi que d'autres polypeptides interagissant avec l'IGFBP-2 ou le modifiant. Parmi les modulateurs préférés de l'IGFBP-2 figurent les anticorps spécifiques à l'IGFBP-2 et les antisens ou ribozymes spécifiques à l'acide nucléique IGFBP-2. Ce type de modulateur est utile pour traiter les cancers dérivés d'un tissu quelconque, et de préférence le cancer de la prostate. L'invention concerne en outre des procédés de traitement d'un sujet atteint du cancer ainsi que des compositions de modulateurs d'IGFBP-2 et des kits renfermant de tels modulateurs.
PCT/US2000/013574 1999-05-17 2000-05-17 Suppression de l'igfbp-2 endogene visant a inhiber le cancer Ceased WO2000069454A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13458199P 1999-05-17 1999-05-17
US60/134,581 1999-05-17

Publications (3)

Publication Number Publication Date
WO2000069454A1 WO2000069454A1 (fr) 2000-11-23
WO2000069454A8 true WO2000069454A8 (fr) 2001-04-12
WO2000069454A9 WO2000069454A9 (fr) 2002-04-18

Family

ID=22464011

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/013574 Ceased WO2000069454A1 (fr) 1999-05-17 2000-05-17 Suppression de l'igfbp-2 endogene visant a inhiber le cancer

Country Status (1)

Country Link
WO (1) WO2000069454A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001290920B2 (en) 2000-09-14 2006-11-23 The University Of British Columbia Antisense insulin-like growth factor binding protein (IGFBP)-2-oligodeoxynucleotides for prostate and other endocrine tumor therapy
FR2821624B1 (fr) 2001-03-01 2004-01-02 Sod Conseils Rech Applic Nouveau polynucleotide utilisable pour moduler la proliferation des cellules cancereuses
WO2002090580A1 (fr) * 2001-05-03 2002-11-14 National Cancer Centre Of Singapore Pte Ltd Identification du cancer du foie par detection de l'expression aberrante de proteines se liant au facteur de croissance analogue a l'insuline
CA2469685C (fr) 2002-01-17 2013-03-12 The University Of British Columbia Oligonucleotides antisens bispecifiques qui inhibent l'igfbp-2 et l'igfbp-5 et procedes d'utilisation associes
KR101086533B1 (ko) 2002-05-24 2011-11-23 쉐링 코포레이션 중화 사람 항-ｉｇｆｒ 항체, 이를 제조하는 방법 및 이를 포함하는 조성물
KR101117673B1 (ko) 2002-08-21 2012-03-07 더 유니버시티 오브 브리티쉬 콜롬비아 암-관련 단백질을 표적으로 하는 알엔에이아이 프로브
WO2005030260A1 (fr) 2003-10-01 2005-04-07 The University Of British Columbia Oligonucleotide bispecifique pour le traitement des malignites du systeme nerveux central
JP2007510434A (ja) 2003-11-12 2007-04-26 シェーリング　コーポレイション 多重遺伝子発現のためのプラスミドシステム
TW200526684A (en) 2003-11-21 2005-08-16 Schering Corp Anti-IGFR1 antibody therapeutic combinations
EP2283831A3 (fr) 2004-12-03 2013-10-23 Merck Sharp & Dohme Corp. Biomarqueurs pour la présélection des patients pour la thérapie anti-IGF1R
CA2659585A1 (fr) * 2006-08-16 2008-02-21 National Research Council Of Canada Procede d'inhibition de l'angiogenese, de la tumorigenese et de l'activite de la cathepsine a l'aide d'une proteine de liaison au facteur de croissance de type insuline
WO2010146059A2 (fr) 2009-06-16 2010-12-23 F. Hoffmann-La Roche Ag Biomarqueurs pour une thérapie par inhibiteur d'igf-1r
CA3146962A1 (fr) 2011-02-11 2012-08-16 The Rockefeller University Traitement de troubles d'angiogenese
CN102590511B (zh) * 2012-02-14 2014-07-23 北京市肿瘤防治研究所 基于igfbp-2自身抗体或其与igfbp-2联合的检测的肿瘤诊断试剂或试剂盒及应用

Also Published As

Publication number Publication date
WO2000069454A1 (fr) 2000-11-23
WO2000069454A9 (fr) 2002-04-18

Similar Documents

Publication Publication Date Title
WO2000069454A8 (fr) Suppression de l'igfbp-2 endogene visant a inhiber le cancer
WO1999022773A3 (fr) Sequences pour cibler les cellules metastatiques
MXPA00007388A (es) Metodos para tratar la pigmentacion de la piel.
WO1996035784A3 (fr) Genes de regulation de la chromatine
WO2002022685A3 (fr) Domaine extracellulaire du muc1 et compositions et procedes pour le traitement du cancer derives de celui-ci
WO2001091805A3 (fr) Composes pour le ciblage des cellules endotheliales, compositions les contenant et leurs procedes d'utilisation
WO2001023405A3 (fr) Traitement therapeutique d'affections causees par le recepteur androgene
WO2003068944A3 (fr) Methodes et compositions permettant de moduler la formation de fibres musculaires de type i a l'aide de pgc-1?-
WO2001072962A3 (fr) Molecules d'acide nucleique specifiques de la prostate ou des testicules, polypeptides, techniques de diagnostic, et traitement therapeutique
WO1999014346A3 (fr) THERAPIES GENIQUES A BASE D'ARNm SENS
TR199902053T2 (xx) Prostat kanserinin immunoterapisine y�nelik bile�ikler ve bunlar�n kullan�lmas�na matuf metodlar.
WO2004039955A3 (fr) Modulateurs de l'angiogenese et de la tumorigenese
WO1998000532A3 (fr) Oligonucleotides provenant des regions non traduites de genes constitutifs, et procede d'utilisation de ces oligonucleotides afin de moduler la croissance cellulaire
WO2001014584A3 (fr) Identification d'agents antiviraux
WO2002004522A3 (fr) Molecules bifonctionnelles et vecteurs complexes avec celles-ci aux fins d'apport cible de genes
ATE275956T1 (de) Veränderung der dns methyltransferase durch kombinationstherapie
WO2002011762A3 (fr) Procedes et compositions utiles pour moduler la croissance des tumeurs
PL346246A1 (en) Modulating multiple lineage kinase proteins
WO1999002704A3 (fr) Phosphatase a double specificite et procedes d'utilisation
WO2000034447A8 (fr) COMPOSES ET METHODES PERMETTANT DE MODULER L'ACTIVATION DE NF-λB
EP0943620A3 (fr) Dérivés de l'acide bétulinique pour inhibition de la croissance des cancers
WO2002054066A3 (fr) Formes non apoptotiques de mort cellulaire et methodes de modulation
ZA200007321B (en) Methods and compositions useful for modulation of angiogenesis using tyrosine kinase Src.
WO2000017346A3 (fr) Molecules hybridantes en epingle a cheveux servant a moduler l'expression genique
DE69739167D1 (de) Zusammensetzungen zur modulierung der länge von telomeren

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: C1

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: C2

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

COP Corrected version of pamphlet

Free format text: PAGES 1/8-8/8, DRAWINGS, REPLACED BY NEW PAGES 1/6-6/6; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP